Cover Image
Market Research Report

Next Generation Sequencing Market Size, Share & Trends Analysis Report By Application (HLA Typing, Consumer Genomics), By Technology, By Workflow, By End Use, By Region, And Segment Forecasts, 2020 - 2027

Published by Grand View Research, Inc. Product code 447144
Published Content info 267 Pages
Delivery time: 2-3 business days
Price
Back to Top
Next Generation Sequencing Market Size, Share & Trends Analysis Report By Application (HLA Typing, Consumer Genomics), By Technology, By Workflow, By End Use, By Region, And Segment Forecasts, 2020 - 2027
Published: February 18, 2020 Content info: 267 Pages
Description

The global next generation sequencing market size is expected to reach USD 23.7 billion by 2027, expanding at a CAGR of 11.7%, according to a new report by Grand View Research, Inc. Numerous advantages offered by high throughput sequencing over other genetic technologies such as sanger-seq and microarray is one of the key driving forces of the market for Next Generation Sequencing (NGS). Furthermore, increasing availability of low input DNA sampling methods that decrease the overall operational costs is anticipated to accelerate the use of next generation sequencing across various research and clinical applications.

Technology offered by New England Biolabs that employs magnetic beads in the template assembly process is anticipated to significantly improve the sample preparation protocols for next generation sequencing. Furthermore, recent technological advancements such as the use of Laboratory Information Management System (LIMS) for genome library automation allow next generation sequencing in a single day at a reasonable cost. These advancements are anticipated to proliferate the number of users of next generation sequencing over the forecast period.

This technology has captured the attention of several companies and investors operating across various domains including basic research, drug discovery and development, reproductive health, and consumer genomics. In addition, the plummeting cost and the added value of next generation sequencing data over conventional ones is anticipated to positively impact the diversification of this technology in other clinical areas, resulting into a lucrative revenue growth.

Further key findings from the report suggest:

In 2019, oncology was estimated as the application with the largest revenue share in the market for next generation sequencing

This can be attributed to the fact that the technology has been largely adopted to decipher the link between cancer and genetics

Moreover, NGS-based genetic testing for cancer predisposition can significantly improve the health outcome and reduce the mortality rate, thereby driving adoption in this segment

The targeted sequencing segment has dominated the revenue share owing to its various benefits over the whole genome segment with respect to the depth of coverage and multiplexing capacities

Significant price drop in sequencing the whole genome is anticipated to drive the segment at a lucrative growth rate

Based on workflow, sequencing accounted for the major revenue share in 2019 in the market for next generation sequencing and is anticipated to maintain its dominance over the forecast period

Being a key step, the end-users are making major investments in the seq-step, compared to sample preparation and data analysis

Moreover, the key developers are engaged in introducing new seq-platforms with enhanced capabilities and efficiency. These factors have led the segment in terms of revenue over the past years

Academic research entities are the largest end-users in terms of revenue generation owing to the high penetration of seq-technology in research activities

On the other hand, this technology is making continued growth in clinical research and within clinical settings

A substantial number of researchers are engaged in conducting translational research to accelerate the adoption of seq-technology in clinical diagnostics

North American accounted for the maximum revenue share owing to the presence of integrated platform base in U.S.

Presence of Illumina, the major player of next generation sequencing market for U.S. is another major factor that has driven the revenue share of this region in the past years

Asia Pacific is projected to mark fastest growth owing to the increase in number of domestic developers in China coupled with the expansion of molecular diagnostics area

Some major participants in the market for next generation sequencing are Illumina Inc.; F Hoffman-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; and BGI

The companies are collaborating with diagnostic players to extend the use of their platforms in clinical settings

For instance, Illumina has partnered with China's KingMed Diagnostics for use of its platform in oncology and hereditary disease testing.

Table of Contents
Product Code: 978-1-68038-428-4

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Information Procurement
    • 1.1.1 Purchased database:
    • 1.1.2 GVR's internal database
    • 1.1.3 Secondary sources:
    • 1.1.4 Third Party Perspective:
    • 1.1.5 Primary Research:
  • 1.2 Information or Data Analysis
  • 1.3 Market Formulation & Validation
  • 1.4 Region Wise Market Calculation
    • 1.4.1 Region wise market: Base estimates
    • 1.4.2 Global market: CAGR calculation
    • 1.4.3 Region based segment share calculation

Chapter 2 Executive Summary

  • 2.1 Next Generation Sequencing Market Outlook, 2016 - 2027
  • 2.2 Next Generation Sequencing Market : Segment Outlook, 2016 - 2027
  • 2.3 Next Generation Sequencing Market : Competitive Insights

Chapter 3 Next Generation Sequencing Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Related/ancillary market outlook
  • 3.2 Penetration & Growth Prospect Mapping for Applications, 2019
  • 3.3 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
  • 3.4 Product Pipeline Analysis, by Stage
  • 3.5 Cost Structure Analysis
  • 3.6 User Perspective Analysis
    • 3.6.1 Consumer behavior analysis
    • 3.6.2 Market influencer analysis
  • 3.7 Procedure Cost Analysis/Breakdown
  • 3.8 List of Key End-users By Region, By Product, By Country
  • 3.9 Technology Overview
    • 3.9.1 Technology timeline
  • 3.10 Regulatory Framework
    • 3.10.1 Next generation sequencing reimbursement environment
      • 3.10.1.1 Gap fill approach for reimbursement of NGS tests
      • 3.10.1.2 Role of the commercial payers
      • 3.10.1.2.1 Payer perspectives for developing coverage policy for Next Generation Tumor Sequencing Panels (NGTS)
      • 3.10.1.2.2 Role of diagnostic laboratories and pathology centres
      • 3.10.1.3 North America
      • 3.10.1.3.1 U.S.
      • 3.10.1.3.2 Canada
      • 3.10.1.4 Europe
      • 3.10.1.4.1 U.K.
      • 3.10.1.4.2 Germany
      • 3.10.1.4.3 Spain
      • 3.10.1.5 Asia Pacific
      • 3.10.1.6 Latin America
      • 3.10.1.7 Middle East Africa
    • 3.10.2 Next generation sequencing regulatory environment
  • 3.11 Next Generation Sequencing Market - Market Dynamics
    • 3.11.1 Market driver analysis
      • 3.11.1.1 Exponentially decreasing costs for genetic sequencing
      • 3.11.1.2 Development of companion diagnostics and personalized medicine
      • 3.11.1.3 Rise in competition amongst prominent market entities
      • 3.11.1.4 Rising clinical opportunity for NGS technology
      • 3.11.1.5 Technological advancements in cloud computing and data integration
      • 3.11.1.6 Growing healthcare expenditure supporting development of effective PM diagnostic & therapeutic procedures for cancer
      • 3.11.1.7 Increasing prevalence of cancer
    • 3.11.2 Market restraint analysis
      • 3.11.2.1 Lack of computational efficiency for data management
      • 3.11.2.2 Non-value based NGS reimbursement policy and regulation status
    • 3.11.3 Market challenges analysis
      • 3.11.3.1 Challenges associated with NGS implementation
  • 3.12 Next Generation Sequencing Market Analysis Tools
    • 3.12.1 Industry Analysis - Porter's
      • 3.12.1.1 Supplier power : Low bargaining power of suppliers due to the complex nature of NGS products
      • 3.12.1.2 Buyer power: Moderate bargaining power of buyer because of a low number of approved products for genome, exome and partial sequencing
      • 3.12.1.3 Substitution threat: Low threat of substitution owing to highly specific nature of genome sequencing
      • 3.12.1.4 New entrants threat: Threat of new entrant is low due presence of prominent players
      • 3.12.1.5 Competitive rivalry: High competitive rivalry due ongoing struggle among the players
    • 3.12.2 PESTEL analysis
      • 3.12.2.1 Political landscape
      • 3.12.2.2 Environmental landscape
      • 3.12.2.3 Social landscape
      • 3.12.2.4 Technology landscape
      • 3.12.2.5 Legal landscape
    • 3.12.3 Major deals & strategic alliances analysis
      • 3.12.3.1 Joint ventures
      • 3.12.3.2 Mergers & acquisitions
      • 3.12.3.3 Licensing & partnership
      • 3.12.3.4 Technology collaborations
      • 3.12.3.5 Strategic divestments
    • 3.12.4 Market entry strategies
    • 3.12.5 Case studies
  • 3.13 NGS Platform Penetration Mapping, 2019
    • 3.13.1 Next Generation Sequencing Market: Regional Market Share, 2019
    • 3.13.2 Next Generation Sequencing North America Regulatory and Political Landscape Analysis, 2019
      • 3.13.2.1 U.S.
      • 3.13.2.2 Canada
    • 3.13.3 Next Generation Sequencing Europe Regulatory and Political Landscape Analysis, 2019
      • 3.13.3.1 U.K.
      • 3.13.3.2 Germany
      • 3.13.3.3 France
      • 3.13.3.4 Spain
    • 3.13.4 Next Generation Sequencing Asia Pacific Regulatory and Political Landscape Analysis, 2019
      • 3.13.4.1 Japan
      • 3.13.4.2 China
    • 3.13.5 Next Generation Sequencing Latin America Regulatory and Political Landscape Analysis, 2019
      • 3.13.5.1 Brazil
      • 3.13.5.2 Mexico
      • 3.13.5.3 Argentina
    • 3.13.6 Next Generation Sequencing Middle East & Africa Regulatory and Political Landscape Analysis, 2019
      • 3.13.6.1 South Africa
      • 3.13.6.2 Qatar
      • 3.13.6.3 Kuwait
      • 3.13.6.4 UAE
      • 3.13.6.5 Saudi Arabia

Chapter 4 Next Generation Sequencing Market: Competitive Analysis

  • 4.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 4.2 Company/Competition Categorization
  • 4.3 Vendor Landscape
      • 4.3.1.1 List of key distributors and channel partners
      • 4.3.1.2 Key customers
      • 4.3.1.3 Key company market share analysis, 2019
    • 4.3.2 Public Companies
      • 4.3.2.1 Company market position analysis
      • 4.3.2.2 Company market share/ranking by region
      • 4.3.2.3 Competitive dashboard analysis
      • 4.3.2.4 Market differentiators
      • 4.3.2.5 Synergy analysis: Major deals & strategic alliances
    • 4.3.3 Private Companies
      • 4.3.3.1 List of key emerging companies
      • 4.3.3.2 Funding outlook
      • 4.3.3.3 Regional network map
      • 4.3.3.4 Company market position analysis
      • 4.3.3.5 Supplier Ranking

Chapter 5 Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

  • 5.1 Definitions & Scope
  • 5.2 Technology Market Share Analysis, 2019 & 2027
  • 5.3 Next Generation Sequencing Market: Technology Movement Analysis, 2019 & 2027
  • 5.4 Global Next Generation Sequencing Market, by Technology, 2016 to 2027
  • 5.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
    • 5.5.1 Whole genome sequencing
      • 5.5.1.1 Global whole genome sequencing market, 2016 - 2027 (USD Million)
    • 5.5.2 Whole exome sequencing
      • 5.5.2.1 Global whole exome sequencing market, 2016 - 2027 (USD Million)
    • 5.5.3 Targeted sequencing & resequencing
      • 5.5.3.1 Global targeted sequencing & resequencing market, 2016 - 2027 (USD Million)
      • 5.5.3.1.1 DNA based targeted sequencing & resequencing
      • 5.5.3.1.2 Global DNA based targeted sequencing & resequencing market, 2016 - 2027 (USD Million)
      • 5.5.3.2 RNA-based targeted sequencing & resequencing
      • 5.5.3.2.1 Global RNA based targeted sequencing & resequencing market, 2016 - 2027 (USD Million)

Chapter 6 Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

  • 6.1 Definitions & Scope
  • 6.2 Application Market Share Analysis, 2019 & 2027
  • 6.3 Next Generation Sequencing Market: Application Movement Analysis, 2019 & 2027
  • 6.4 Global Next Generation Sequencing Market, by Application, 2016 to 2027
  • 6.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
    • 6.5.1 Oncology
      • 6.5.1.1 Global oncology market, 2016 - 2027 (USD Million)
      • 6.5.1.2 Diagnostics and screening
      • 6.5.1.2.1 Diagnostics and screening market, 2016 - 2027 (USD Million)
      • 6.5.1.2.2 Oncology screening
      • 6.5.1.2.2.1 Oncology screening market, 2016 - 2027 (USD Million)
      • 6.5.1.2.2.2 Sporadic cancer screening market, 2016 - 2027 (USD Million)
      • 6.5.1.2.2.3 Inherited cancer screening market, 2016 - 2027 (USD Million)
      • 6.5.1.2.3 Companion diagnostics market, 2016 - 2027 (USD Million)
      • 6.5.1.2.4 Other diagnostics market, 2016 - 2027 (USD Million)
      • 6.5.1.3 Research studies market, 2016 - 2027 (USD Million)
    • 6.5.2 Clinical investigation
      • 6.5.2.1 Global clinical investigation market, 2016 - 2027 (USD Million)
      • 6.5.2.2 Infectious diseases
      • 6.5.2.2.1 Global infectious diseases market, 2016 - 2027 (USD Million)
      • 6.5.2.3 Inherited diseases
      • 6.5.2.3.1 Global inherited diseases market, 2016 - 2027 (USD Million)
      • 6.5.2.4 Idiopathic diseases
      • 6.5.2.4.1 Global idiopathic diseases market, 2016 - 2027 (USD Million)
      • 6.5.2.6 Non-communicable/other diseases
      • 6.5.2.6.1 Global non-communicable/other diseases market, 2016 - 2027 (USD Million)
    • 6.5.3 Reproductive health
      • 6.5.3.1 Global reproductive health market, 2016 - 2027 (USD Million)
      • 6.5.3.2 NIPT
      • 6.5.3.2.1 Global NIPT market, 2016 - 2027 (USD Million)
      • 6.5.3.2.2 Global aneuploidy market, 2016 - 2027 (USD Million)
      • 6.5.3.2.3 Global microdeletions market, 2016 - 2027 (USD Million)
      • 6.5.3.3 PGT
      • 6.5.3.3.1 Global NGS PGT market, 2016 - 2027 (USD Million)
      • 6.2.3.4 New-born/genetic screening
      • 6.5.3.4.1 Global newborn/genetic screening market, 2016 - 2027 (USD Million)
      • 6.2.3.6 Single gene analysis
      • 6.5.3.6.1 Single gene analysis market, 2016 - 2027 (USD Million)
    • 6.5.4 HLA typing/immune system monitoring
      • 6.5.4.1 Global HLA typing/immune system monitoring market, 2016 - 2027 (USD Million)
    • 6.5.6 Metagenomics, epidemiology & drug development
      • 6.5.6.1 Global metagenomics, epidemiology & drug development market, 2016 - 2027 (USD Million)
    • 6.5.6 Agrigenomics & forensics
      • 6.5.6.1 Global agrigenomics & forensics market, 2016 - 2027 (USD Million)
    • 6.5.7 Consumer genomics
      • 6.5.7.1 Global consumer genomics market, 2016 - 2027 (USD Million)

Chapter 7 Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

  • 7.1 Definitions & Scope
  • 7.2 Workflow Market Share Analysis, 2019 & 2027
  • 7.3 Next Generation Sequencing Market: Workflow Movement Analysis, 2019 & 2027
  • 7.4 Global Next Generation Sequencing Market by Workflow, 2019 & 2027
  • 7.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
    • 7.5.1 Pre-Sequencing
      • 7.5.1.1 Global pre-sequencing market, 2016 - 2027 (USD Million)
      • 7.5.1.2 NGS library preparation kits
      • 7.5.1.2.1 Global NGS library preparation kits market, 2016 - 2027 (USD Million)
      • 7.5.1.3 NGS semi-automated library preparation
      • 7.5.1.3.1 Global NGS semi-automated library preparation market, 2016 - 2027 (USD Million)
      • 7.5.1.4 NGS automated library preparation
      • 7.5.1.4.1 Global NGS automated library preparation market, 2016 - 2027 (USD Million)
      • 7.5.1.5 Clonal amplification
      • 7.5.1.5.1 Global clonal amplification market, 2016 - 2027 (USD Million)
    • 7.5.2 Sequencing
      • 7.5.2.1 Global sequencing market, 2016 - 2027 (USD Million)
    • 7.5.3 Data analysis
      • 7.5.3.1 Global data analysis market, 2016 - 2027 (USD Million)
      • 7.5.3.2 NGS primary data analysis
      • 7.5.3.2.1 Global NGS primary data analysis market, 2016 - 2027 (USD Million)
      • 7.5.3.3 NGS secondary data analysis
      • 7.5.3.3.1 Global NGS secondary data analysis market, 2016 - 2027 (USD Million)
      • 7.5.3.4 NGS tertiary data analysis
      • 7.5.3.4.1 Global NGS tertiary data analysis services market, 2016 - 2027 (USD Million)

Chapter 8 Next Generation Sequencing Market Categorization: End-use Estimates & Trend Analysis

  • 8.1 Definitions & Scope
  • 8.2 End-use Market Share Analysis, 2019 & 2027
  • 8.3 Next Generation Sequencing Market: End-Use Movement Analysis, 2019 & 2027
  • 8.4 Global Next Generation Sequencing Market, by End use, 2016 to 2027
  • 8.5 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
    • 8.5.1 Academic research
      • 8.5.1.1 Global academic research market, 2016 - 2027 (USD Million)
    • 8.5.2 Clinical research
      • 8.5.2.1 Global clinical research market, 2016 - 2027 (USD Million)
    • 8.5.3 Hospitals & clinics
      • 8.5.3.1 Global hospitals & clinics market2016 - 2027 (USD Million)
    • 8.5.4 Pharma & biotech entities
      • 8.5.4.1 Global pharma & biotech entities market, 2016 - 2027 (USD Million)
    • 8.5.5 Other users
      • 8.5.5.1 Global other users market, 2016 - 2027 (USD Million)

Chapter 9 Next Generation Sequencing Market Categorization: Regional Estimates & Trend Analysis, by Product & Service Type, Application, Technology, Workflow, & End-use

  • 9.1 Next generation sequencing market share by region, 2019 & 2027
  • 9.2 Regional Market Share and Leading Players, 2019
    • 9.2.1 North America
    • 9.2.2 Europe
    • 9.2.3 Asia Pacific
    • 9.2.4 Latin America
    • 9.2.5 Middle East & Africa
  • 9.3 North America
    • 9.3.1 North America next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.3.2 U.S.
      • 9.3.2.1 U.S. next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.3.3 Canada
      • 9.3.3.1 Canada next generation sequencing market, 2016 - 2027 (USD Million)
  • 9.4 Europe
    • 9.4.1 Europe next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.4.2 Germany
      • 9.4.2.1 Germany next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.4.3 U.K.
      • 9.4.3.1 U.K. next generation sequencing market, 2016 - 2027 (USD Million)
  • 9.5 Asia Pacific
    • 9.5.1 Asia Pacific next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.5.2 Japan
      • 9.5.2.1 Japan next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.5.3 China
      • 9.5.3.1 China next generation sequencing market, 2016 - 2027 (USD Million)
  • 9.6 Latin America
    • 9.6.1 Latin America next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.6.2 Brazil
      • 9.6.2.1 Brazil next generation sequencing market, 2016 - 2027 (USD Million)
  • 9.7 Middle East & Africa
    • 9.7.1 Middle East & Africa next generation sequencing market, 2016 - 2027 (USD Million)
    • 9.7.2 South Africa
      • 9.7.2.1 South Africa next generation sequencing market, 2016 - 2027 (USD Million)

Chapter 10 Competitive Landscape

  • 10.1 Strategy Framework
  • 10.2 Market Participation Categorization
  • 10.3 Next-Generation Sequencing Vendor's Landscape
    • 10.3.1 Champions
    • 10.3.2 Innovators
    • 10.3.3 Emerging players
    • 10.3.4 Market pillars
  • 10.4 Company Profiles
    • 10.4.1 Illumina, Inc.
      • 10.4.1.1 Company overview
      • 10.4.1.2 Financial performance
      • 10.4.1.3 Product benchmarking
      • 10.4.1.4 Strategic initiatives
    • 10.4.2 F. Hoffmann-La Roche Ltd.
      • 10.4.2.1 Company overview
      • 10.4.2.2 Financial performance
      • 10.4.2.3 Product benchmarking
      • 10.4.2.4 Strategic initiatives
    • 10.4.3 Agilent Technologies, Inc.
      • 10.4.3.1 Company overview
      • 10.4.3.2 Financial performance
      • 10.4.3.3 Product benchmarking
      • 10.4.3.4 Strategic initiatives
    • 10.4.4 PierianDx
      • 10.4.4.1 Company overview
      • 10.4.4.1.1 Tute Genomics
      • 10.4.4.1.2 Knome, Inc.
      • 10.4.4.2 Financial performance
      • 10.4.4.3 Product benchmarking
      • 10.4.4.4 Strategic initiatives
    • 10.4.5 Genomatix GmbH
      • 10.4.5.1 Company overview
      • 10.4.5.2 Financial performance
      • 10.4.5.3 Product benchmarking
      • 10.4.5.4 Strategic initiatives
    • 10.4.6 Eurofins GATC Biotech GmbH
      • 10.4.6.1 Company overview
      • 10.4.6.2 Financial performance
      • 10.4.6.3 Product benchmarking
      • 10.4.6.4 Strategic initiatives
    • 10.4.7 Oxford Nanopore Technologies
      • 10.4.7.1 Company overview
      • 10.4.7.2 Financial performance
      • 10.4.7.3 Product benchmarking
      • 10.4.7.4 Strategic initiatives
    • 10.4.8 Macrogen, Inc.
      • 10.4.8.1 Company overview
      • 10.4.8.2 Financial performance
      • 10.4.8.3 Product benchmarking
      • 10.4.8.4 Strategic initiatives
    • 10.4.9 Thermo Fisher Scientific, Inc.
      • 10.4.9.1 Company overview
      • 10.4.9.1.1 Life Technologies Corp.
      • 10.4.9.2 Financial performance
      • 10.4.9.3 Product benchmarking
      • 10.4.9.4 Strategic initiatives
    • 10.4.10 DNASTAR, Inc.
      • 10.4.10.1 Company overview
      • 10.4.10.2 Financial Performance
      • 10.4.10.3 Product benchmarking
      • 10.4.10.4 Strategic initiatives
    • 10.4.11 Biomatters Ltd.
      • 10.4.11.1 Company overview
      • 10.4.11.2 Financial performance
      • 10.4.11.3 Product benchmarking
      • 10.4.11.4 Strategic initiatives
    • 10.4.12 QIAGEN
      • 10.4.12.1 Company overview
      • 10.4.12.1.1 Ingenuity
      • 10.4.12.1.2 CLC Bio
      • 10.4.12.2 Financial performance
      • 10.4.12.3 Product benchmarking
      • 10.4.12.4 Strategic initiatives
    • 10.4.13 BGI
      • 10.4.13.1 Company overview
      • 10.4.13.1.1 Complete Genomics Incorporated
      • 10.4.13.2 Financial performance
      • 10.4.13.3 Product benchmarking
      • 10.4.13.4 Strategic initiatives
    • 10.4.14 Perkin Elmer, Inc.
      • 10.4.14.1 Company overview
      • 10.4.14.2 Financial performance
      • 10.4.14.3 Product benchmarking
      • 10.4.14.4 Strategic initiatives
    • 10.4.15 Pacific Biosciences of California, Inc.
      • 10.4.15.1 Company overview
      • 10.4.15.2 Financial performance
      • 10.4.15.3 Product benchmarking
      • 10.4.15.4 Strategic initiatives
    • 10.4.16 Partek Incorporated
      • 10.4.16.1 Company overview
      • 10.4.16.2 Financial performance
      • 10.4.16.3 Product benchmarking
      • 10.4.16.4 Strategic initiatives
    • 10.4.17 Bio-Rad Laboratories, Inc.
      • 10.4.17.1 Company overview
      • 10.4.17.2 GnuBio
      • 10.4.17.2.1 Company overview
      • 10.4.17.3 Financial performance
      • 10.4.17.4 Product benchmarking
      • 10.4.17.5 Strategic initiatives
    • 10.4.18 Myriad Genetics, Inc.
      • 10.4.18.1 Company overview
      • 10.4.18.2 Financial performance
      • 10.4.18.3 Product benchmarking
      • 10.4.18.4 Strategic initiatives
    • 10.4.19 Hologic, Inc. (Gen-Probe Incorporated)
      • 10.4.19.1 Company overview
      • 10.4.19.2 Financial performance
      • 10.4.19.3 Product benchmarking
      • 10.4.19.4 Strategic initiatives
    • 10.4.20 Horizon Discovery Group plc
      • 10.4.20.1 Company overview
      • 10.4.20.2 Financial performance
      • 10.4.20.3 Product benchmarking
      • 10.4.20.4 Strategic initiatives
    • 10.4.21 LGC Limited
      • 10.4.21.1 Company overview
      • 10.4.21.2 SeraCare
      • 10.4.21.2.1 Company overview
      • 10.4.21.3 Financial performance (LGC Limited)
      • 10.4.21.3.1 Financial performance
      • 10.4.21.4 Product benchmarking
      • 10.4.21.5 Strategic initiatives
    • 10.4.22 Vela Diagnostics
      • 10.4.22.1 Company overview
      • 10.4.22.2 Financial performance
      • 10.4.22.3 Product benchmarking
      • 10.4.22.4 Strategic initiatives
  • 10.5 List of Companies

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 Country share estimation
  • TABLE 3 Healthcare expenditure, 2015
  • TABLE 4 NGS top platforms
  • TABLE 5 Base pairs sequenced using WGS, WES, and targeted sequencing &resequencing
  • TABLE 6 Clonal amplification products in the market
  • TABLE 7 North America next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 8 North America next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 9 North America next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 10 North America next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 11 North America NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 12 North America NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 13 North America next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 14 North America next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 15 North America targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 16 North America next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 17 North America NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 18 North America NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 19 North America next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 20 U.S. next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 21 U.S. next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 22 U.S. next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 23 U.S. next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 24 U.S. NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 25 U.S. NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 26 U.S. next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 27 U.S. next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 28 U.S. targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 29 U.S. next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 30 U.S. NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 31 U.S. NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 32 U.S. next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 33 Canada next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 34 Canada next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 35 Canada next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 36 Canada next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 37 Canada NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 38 Canada NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 39 Canada next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 40 Canada next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 41 Canada targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 42 Canada next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 43 Canada NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 44 Canada NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 45 Canada next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 46 Europe next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 47 Europe next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 48 Europe next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 49 Europe next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 50 Europe NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 51 Europe NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 52 Europe next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 53 Europe next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 54 Europe targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 55 Europe next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 56 Europe NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 57 Europe NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 58 Europe next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 59 Germany next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 60 Germany next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 61 Germany next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 62 Germany next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 63 Germany NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 64 Germany NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 65 Germany next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 66 Germany next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 67 Germany targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 68 Germany next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 69 Germany NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 70 Germany NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 71 Germany next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 72 U.K. next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 73 U.K. next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 74 U.K. next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 75 U.K. next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 76 U.K. NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 77 U.K. NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 78 U.K. next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 79 U.K. next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 80 U.K. targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 81 U.K. next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 82 U.K. NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 83 U.K. NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 84 U.K. next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 85 Asia Pacific next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 86 Asia Pacific next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 87 Asia Pacific next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 88 Asia Pacific next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 89 Asia Pacific NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 90 Asia Pacific NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 91 Asia Pacific next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 92 Asia Pacific next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 93 Asia Pacific targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 94 Asia Pacific next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 95 Asia Pacific NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 96 Asia Pacific NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 97 Asia Pacific next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 98 Japan next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 99 Japan next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 100 Japan next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 101 Japan next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 102 Japan NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 103 Japan NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 104 Japan next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 105 Japan next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 106 Japan targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 107 Japan next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 108 Japan NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 109 Japan NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 110 Japan next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 111 China next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 112 China next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 113 China next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 114 China next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 115 China NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 116 China NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 117 China next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 118 China next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 119 China targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 120 China next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 121 China NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 122 China NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 123 China next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 124 Latin America next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 125 Latin America next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 126 Latin America next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 127 Latin America next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 128 Latin America NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 129 Latin America NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 130 Latin America next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 131 Latin America next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 132 Latin America targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 133 Latin America next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 134 Latin America NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 135 Latin America NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 136 Latin America next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 137 Brazil next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 138 Brazil next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 139 Brazil next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 140 Brazil next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 141 Brazil NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 142 Brazil NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 143 Brazil next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 144 Brazil next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 145 Brazil targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 146 Brazil next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 147 Brazil NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 148 Brazil NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 149 Brazil next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 150 MEA next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 151 MEA next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 152 MEA next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 153 MEA next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 154 MEA NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 155 MEA NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 156 MEA next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 157 MEA next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 158 MEA targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 159 MEA next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 160 MEA NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 161 MEA NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 162 MEA next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)
  • TABLE 163 South Africa next generation sequencing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 164 South Africa next generation sequencing for oncology market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 165 South Africa next generation sequencing for oncology diagnostics & screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 166 South Africa next generation sequencing for oncology screening market, by application, 2016 - 2027 (USD Million)
  • TABLE 167 South Africa NGS clinical investigation market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 168 South Africa NGS reproductive health market estimates & forecasts, by application, 2016 - 2027 (USD Million)
  • TABLE 169 South Africa next generation sequencing NIPT market, by application, 2016 - 2027 (USD Million)
  • TABLE 170 South Africa next generation sequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 171 South Africa targeted sequencing/resequencing market estimates & forecasts, by technology, 2016 - 2027 (USD Million)
  • TABLE 172 South Africa next generation sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 173 South Africa NGS pre-sequencing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 174 South Africa NGS data analysis market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
  • TABLE 175 South Africa next generation sequencing market estimates & forecasts, by end use, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market summary
  • FIG. 9 Penetration & growth prospect mapping for applications, 2019
  • FIG. 10 Penetration & growth prospect mapping for prominent industry players, 2019
  • FIG. 11 Payer perspectives for developing coverage policy for Next Generation Tumour Sequencing Panels (NGTS)
  • FIG. 12 Market trends & outlook
  • FIG. 13 Market driver relevance analysis (Current & future impact)
  • FIG. 14 Cost per raw megabase (Mb) of DNA sequence (USD)
  • FIG. 15 Cost per genome
  • FIG. 16 Expected rise in expenditure for cancer treatment (USD Billion)
  • FIG. 17 Global cancer prevalence
  • FIG. 18 Market restraint relevance analysis (Current & future impact)
  • FIG. 19 Percentage of NGS sequencing reimbursement from payers
  • FIG. 20 Bottlenecks associated with the implementation of NGS
  • FIG. 21 Porter's Five Forces Analysis
  • FIG. 22 PESTEL Analysis
  • FIG. 23 NGS platform penetration mapping, 2019
  • FIG. 24 Next generation sequencing market: Regional market share, 2019
  • FIG. 25 Next generation sequencing North America regulatory and political landscape analysis, 2019
  • FIG. 26 Next generation sequencing Europe regulatory and political landscape analysis, 2019
  • FIG. 27 Next generation sequencing Asia Pacific regulatory and political landscape analysis, 2019
  • FIG. 28 Next generation sequencing Latin America regulatory and political landscape analysis, 2019
  • FIG. 29 Next generation sequencing Middle East & Africa regulatory and political landscape analysis 2019
  • FIG. 30 Next generation sequencing market: Application outlook key takeaways
  • FIG. 31 Next generation sequencing market: Application movement analysis
  • FIG. 32 Global oncology market, 2016 - 2027 (USD Million)
  • FIG. 33 Diagnostics and screening market, 2016 - 2027 (USD Million)
  • FIG. 34 Oncology screening market, 2016 - 2027 (USD Million)
  • FIG. 35 Sporadic cancer screening market, 2016 - 2027 (USD Million)
  • FIG. 36 Inherited cancer screening market, 2016 - 2027 (USD Million)
  • FIG. 37 Companion diagnostics market, 2016 - 2027 (USD Million)
  • FIG. 38 Other diagnostics market, 2016 - 2027 (USD Million)
  • FIG. 39 Research studies market, 2016 - 2027 (USD Million)
  • FIG. 40 Global clinical investigation market, 2016 - 2027 (USD Million)
  • FIG. 41 Global infectious diseases market, 2016 - 2027 (USD Million)
  • FIG. 42 Global inherited diseases market, 2016 - 2027 (USD Million)
  • FIG. 43 Global idiopathic diseases market, 2016 - 2027 (USD Million)
  • FIG. 44 Global non-communicable/other diseases market, 2016 - 2027 (USD Million)
  • FIG. 45 Global reproductive health market, 2016 - 2027 (USD Million)
  • FIG. 46 Global NIPT market, 2016 - 2027 (USD Million)
  • FIG. 47 Global aneuploidy market, 2016 - 2027 (USD Million)
  • FIG. 48 Global microdeletions market, 2016 - 2027 (USD Million)
  • FIG. 49 Global NGS PGT market, 2016 - 2027 (USD Million)
  • FIG. 50 Global new-born/genetic screening market, 2016 - 2027 (USD Million)
  • FIG. 51 Single gene analysis market, 2016 - 2027 (USD Million)
  • FIG. 52 Global HLA typing/immune system monitoring market, 2016 - 2027 (USD Million)
  • FIG. 53 Global metagenomics, epidemiology & drug development market, 2016 - 2027 (USD Million)
  • FIG. 54 Global agrigenomics & forensics market, 2016 - 2027 (USD Million)
  • FIG. 55 Global consumer genomics market, 2016 - 2027 (USD Million)
  • FIG. 56 Next generation sequencing market: Technology outlook key takeaways
  • FIG. 57 Global next generation sequencing market: Technology movement analysis
  • FIG. 58 Global whole genome sequencing market, 2016 - 2027 (USD Million)
  • FIG. 59 Global whole exome sequencing market, 2016 - 2027 (USD Million)
  • FIG. 60 Global targeted sequencing & resequencing market, 2016 - 2027 (USD Million)
  • FIG. 61 Global DNA based targeted sequencing & resequencing market, 2016 - 2027 (USD Million)
  • FIG. 62 Global RNA based targeted sequencing & resequencing market, 2016 - 2027 (USD Million)
  • FIG. 63 Next generation sequencing market Workflow outlook key takeaways
  • FIG. 64 Next generation sequencing market: Workflow movement analysis
  • FIG. 65 Global pre-sequencing market, 2016 - 2027 (USD Million)
  • FIG. 66 Global NGS library preparation kits market, 2016 - 2027 (USD Million)
  • FIG. 67 Global NGS semi-automated library preparation market, 2016 - 2027 (USD Million)
  • FIG. 68 Global NGS automated library preparation market, 2016 - 2027 (USD Million)
  • FIG. 69 Global clonal amplification market, 2016 - 2027 (USD Million)
  • FIG. 70 Global sequencing market, 2016 - 2027 (USD Million)
  • FIG. 71 Global data analysis market, 2016 - 2027 (USD Million)
  • FIG. 72 Global NGS primary data analysis market, 2016 - 2027 (USD Million)
  • FIG. 73 Global NGS secondary data analysis market, 2016 - 2027 (USD Million)
  • FIG. 74 Global NGS tertiary data analysis market, 2016 - 2027 (USD Million)
  • FIG. 75 Next generation sequencing market End-use outlook key takeaways
  • FIG. 76 Next generation sequencing market: End-use movement analysis
  • FIG. 77 Global academic research market, 2016 - 2027 (USD Million)
  • FIG. 78 Global clinical research market, 2016 - 2027 (USD Million)
  • FIG. 79 Global hospitals & clinics market, 2016 - 2027 (USD Million)
  • FIG. 80 Global pharma & biotech entities market, 2016 - 2027 (USD Million)
  • FIG. 81 Global other users market, 2016 - 2027 (USD Million)
  • FIG. 82 Regional market place: Key takeaway
  • FIG. 83 Regional sequencing capacity mapping
  • FIG. 84 Next generation regional outlook, 2019 & 2027
  • FIG. 85 North America next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 86 U.S. next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 87 Canada next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 88 Europe next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 89 Germany next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 90 UK next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 91 Asia Pacific next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 92 Japan next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 93 China next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 94 Latin America. next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 95 Brazil next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 96 Middle East & Africa. next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 97 South Africa next generation sequencing market, 2016 - 2027 (USD Million)
  • FIG. 98 Strategy framework
  • FIG. 99 Participant categorization
  • FIG. 100 Next-generation sequencing vendor's landscape
  • FIG. 101 List of companies
Back to Top